Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Merger Agreement with BioCircuit filed as Exhibit 2.1, giving investors access to definitive transaction terms.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Merger Agreement with BioCircuit filed as Exhibit 2.1, giving investors access to definitive transaction terms
- Filing supplements Axogen’s prior Item 1.01 disclosure, indicating the transaction was previously announced
- Exhibit’s contractual representations and warranties are not reliable measures of current business conditions or transaction outcomes
Item 7.01 · Regulation FD Disclosure
- Corrected investor presentation furnished as Exhibit 99.2
- Amendment addresses errors in the investor materials, requiring investors to rely on the corrected presentation
Item EX-99.1 · Exhibit EX-99.1
- Planned $200M cash acquisition of BioCircuit Technologies, subject to customary adjustments and closing conditions
- BioCircuit contributes ~$24M annualized Q2 2026 revenue, $11M 2025 revenue, ~80% gross margins, and $11M standalone EBITDA
- NerveTape is the first FDA-cleared sutureless nerve-repair device, expanding Axogen’s addressable market and reducing microsurgical skill requirements
- Deal expected accretive to revenue growth and adjusted EBITDA margins in Year 1 while Axogen remains free-cash-flow positive
- Substantially all equity-offering proceeds earmarked for consideration, fees, and expenses; closing expected Q4 2026 subject to convertible-note conversion and other conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.